SCHEMBL19784939

SCHEMBL19784939

CCCCn1nnc(-c2ccc(NC(=O)Nc3cnccc3F)cc2)n1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDX3X O00571 3/20 0.65
KDR P35968 2/20 0.49
EIF2AK2 P19525 2/20 0.49
SMN1; SMN2 Q16637 3/20 0.42
POLB P06746 2/20 0.42
LMNA P02545 2/20 0.42
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
S1PR2 O95136 1/20 0.41
S1PR1 P21453 1/20 0.41
S1PR3 Q99500 1/20 0.41
LPAR2 Q9HBW0 1/20 0.41
TRPV1 Q8NER1 1/20 0.41
MAPT P10636 1/20 0.40
AURKA O14965 1/20 0.40
MAPK13 O15264 1/20 0.40
DYRK3 O43781 1/20 0.40
ROCK2 O75116 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17978487 0.89 DDX3X (0.63) DDX3XKDREIF2AK2SMN1; SMN2LMNA
SCHEMBL19784943 0.87 DDX3X (0.77) DDX3XKDREIF2AK2SMN1; SMN2POLB
SCHEMBL17978456 0.80 DDX3X (0.75) DDX3XKDRPOLBLMNANPC1
SCHEMBL17978453 0.78 DDX3X (1.00) DDX3XKDREIF2AK2POLBNPC1
SCHEMBL19784959 0.75 DDX3X (0.93) DDX3XKDREIF2AK2NPC1RAB9A
SCHEMBL19784743 0.71 DDX3X (0.61) DDX3XLMNATRPV1MAPTKDM4E
SCHEMBL27788947 0.68 USP2 (0.61) SMN1; SMN2LMNAS1PR2S1PR1S1PR3
SCHEMBL19403810 0.67 TRPV1 (0.42) DDX3XKDRLMNANPC1RAB9A
SCHEMBL17669987 0.67 KDR (1.00) DDX3XKDREIF2AK2AURKAMAPK13
SCHEMBL17978449 0.65 LMNA (0.71) DDX3XSMN1; SMN2LMNANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180016243-A1 HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) 2018-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180016243-A1 HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS DDX3X, DDX39B, DDX1 DDX3X 1/4885KDR 4472/4885EIF2AK2 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.